BioCentury
ARTICLE | Clinical News

Zevalin ibritumomab tiuxetan regulatory update

July 8, 2002 7:00 AM UTC

IDPH said European approval for Zevalin radioimmunotherapy has been delayed because of compliance issues at the fill/finish provider, DSM Pharmaceuticals Inc. (Greenville, N.C.). IDPH and partner SCH ...